Featured Research

from universities, journals, and other organizations

Protein Predicts Gleevec Resistance In Gastrointestinal Tumors

Date:
May 15, 2008
Source:
Fox Chase Cancer Center
Summary:
Excess amounts of a protein called IGF-1R in patients with gastrointestinal stromal tumors could indicate that the patient would be less responsive to Gleevec. Preliminary studies have shown that GIST cells, especially Gleevec-resistant cells, might respond well to agents in development for treatment-resistant breast cancer, which is also marked by excessive IGF-1R production. IGF-1R could also serve as a marker to identify Gleevec-resistant patients before therapy begins, when alternative treatments would be most effective.

Excess amounts of a protein called IGF-1R in patients with gastrointestinal stromal tumors (GISTs) could indicate that the patient would be less responsive to the drug imatinib mesylate (known as Gleevec), according to Andrew K. Godwin, Ph.D., a researcher at the Fox Chase Cancer Center in Philadelphia. Preliminary studies have shown that GIST cells, especially Gleevec-resistant cells, might respond well to agents in development for treatment-resistant breast cancer, a form of breast cancer also marked by excessive production of the IGF-1R protein. IGF-1R could also serve as a marker to identify this subset of GIST patients before therapy begins, when alternative treatments would be most effective, the researcher says.

"A small percentage of adult gastrointestinal stromal tumors -- and most pediatric cases --are often less responsive to Gleevec," says Godwin, Director of Fox Chase's Clinical Molecular Genetics Laboratory. "We have found that tumors in many of these cases coincide with an overabundance of the IGF-1R protein."

In most occurrences, GISTs develop through a mutation in the genes c-KIT or PDGFR±, both of which are targets of Gleevec. GISTs without those mutations, known as "wild type," as well as pediatric GISTs, do not often respond well to treatment with Gleevec.

The Fox Chase researchers found that, when compared to mutant GISTs, the DNA of wild type and pediatric GISTs exhibited more copies of the IGF1R gene. These tumors also produced many more copies of the IGF-1R protein, which serves to promote cell survival, proliferation and growth in normal cells. In tumors, an excess of IGF-1R allows cancer cells to grow out of control, breaking the normal control mechanisms that are an inherent part of cell function. In the laboratory, the researchers found that drugs that decrease IGF-1R activity induced the death of tumor cells.

According to Godwin and his colleagues, their studies are the first to reveal that the development of wild type GISTs could be related to abnormal expression of IGF-1R.

"IGF-1R overproduction seems to be a common factor in a number of different cancers, and there are several IGF-1R-targeted therapeutic agents in development and in clinical trials that might also be effective against GISTs," Godwin says. "As is often the case with targeted therapies, we need to find the right patient for the drug as much as we need to find the right drug for the disease."

Godwin and his colleagues will soon publish the full results of their studies and have begun investigating the possibility of testing for IGF-1R in clinical trials at Fox Chase.

Godwin presents his findings at the 2008 Annual Meeting of the American Society of Clinical Oncology, held May 30 through June 3 in Chicago.


Story Source:

The above story is based on materials provided by Fox Chase Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

Fox Chase Cancer Center. "Protein Predicts Gleevec Resistance In Gastrointestinal Tumors." ScienceDaily. ScienceDaily, 15 May 2008. <www.sciencedaily.com/releases/2008/05/080515215858.htm>.
Fox Chase Cancer Center. (2008, May 15). Protein Predicts Gleevec Resistance In Gastrointestinal Tumors. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2008/05/080515215858.htm
Fox Chase Cancer Center. "Protein Predicts Gleevec Resistance In Gastrointestinal Tumors." ScienceDaily. www.sciencedaily.com/releases/2008/05/080515215858.htm (accessed August 22, 2014).

Share This




More Health & Medicine News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) — An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) — Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) — It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com
Lost Brain Cells To Blame For Sleep Problems Among Seniors

Lost Brain Cells To Blame For Sleep Problems Among Seniors

Newsy (Aug. 21, 2014) — According to a new study, elderly people might have trouble sleeping because of the loss of a certain group of neurons in the brain. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins